Read twice and referred to the Committee on Finance.
This bill (Share the Savings with Seniors Act) amends Medicare Part D rules to limit how much cost-sharing beneficiaries pay for certain chronic care drugs beginning in plan years on or after January 1, 2027. For costs below the annual deductible, patient cost-sharing for a covered chronic care drug may not exceed the drug’s net price; for costs above the deductible and below the out-of-pocket threshold, any coinsurance must be calculated as a percentage of the drug’s net price (with a narrow exception for plans that use fixed copayments not tied to a drug price).
Extent of federal intervention: liberals more comfortable with the mandate to tie coinsurance to net price; conservatives see this as overreach.
Relative to its intended legislative type, this bill is a focused statutory amendment that establishes new cost-sharing rules for a defined class of Part D drugs, but it leaves several operational, fiscal, and oversight details to be specified by the Secretary via regulation.
This bill (Share the Savings with Seniors Act) amends Medicare Part D rules to limit how much cost-sharing beneficiaries pay for certain chronic care drugs beginning in plan years on or after January 1, 2027.
For costs below the annual deductible, patient cost-sharing for a covered chronic care drug may not exceed the drug’s net price; for costs above the deductible and below the out-of-pocket threshold, any coinsurance must be calculated as a percentage of the drug’s net price (with a narrow exception for plans that use fixed copayments not tied to a drug price).
The bill defines which drug categories count as "chronic care drugs" using USP Medicare Model Guidelines (explicitly listing categories such as non‑insulin blood glucose regulators, inhaled corticosteroids, bronchodilators, anticoagulants, and certain cardiovascular agents) and defines "net price" as negotiated price net of manufacturer concessions expected or received.
On content alone, the bill is a focused, administratively framed attempt to reduce seniors’ cost‑sharing for a set of chronic drugs — a goal with public appeal. However, it alters the pricing and rebate architecture of Part D without explicit fiscal offsets and would likely draw opposition from powerful industry stakeholders and require complex regulatory work. These factors reduce the chances of passage as a standalone measure, though its prospects would improve if folded into a larger bipartisan package or exchanged for concessions.
Relative to its intended legislative type, this bill is a focused statutory amendment that establishes new cost-sharing rules for a defined class of Part D drugs, but it leaves several operational, fiscal, and oversight details to be specified by the Secretary via regulation.
Extent of federal intervention: liberals more comfortable with the mandate to tie coinsurance to net price; conservatives see this as overreach.
These are examples from the analysis, not a ranked list of the most-affected groups.
Extent of federal intervention: liberals more comfortable with the mandate to tie coinsurance to net price; conservatives see this as overreach.
A mainstream progressive would likely view the bill favorably as a targeted consumer-protection measure that reduces out-of-pocket costs for seniors on ongoing medications and helps ensure manufacturer price concessions reduce patient burden.
They would note it uses the concept of "net price" to limit coinsurance and would welcome the focus on chronic conditions that disproportionately affect older adults.
However, they would be concerned that the bill excludes insulins from the glucose regulator category and that the scope is limited to certain USP categories rather than a broader set of essential drugs.
A moderate would see this as a pragmatic, targeted reform to lower seniors' cost-sharing for ongoing medications without upending the entire Part D system.
They would appreciate the phased start date (2027), the limited scope to certain drug classes, and the copayment exception that preserves existing flat‑copay plan designs.
At the same time, they would be cautious about unintended consequences for premiums, plan viability, and administrative complexity and would look for evidence and safeguards that the change benefits patients overall without large budgetary side effects.
A mainstream conservative would likely be skeptical of the bill because it directs how private Part D plans must calculate patient cost-sharing and interferes with negotiated pricing dynamics between plans, PBMs, and manufacturers.
They would view the net-price requirement as an added regulatory constraint that could distort market negotiations and increase administrative costs.
The copayment exception and limited drug categories reduce but do not eliminate concerns about federal overreach and potential downstream effects on premiums or plan offerings.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, the bill is a focused, administratively framed attempt to reduce seniors’ cost‑sharing for a set of chronic drugs — a goal with public appeal. However, it alters the pricing and rebate architecture of Part D without explicit fiscal offsets and would likely draw opposition from powerful industry stakeholders and require complex regulatory work. These factors reduce the chances of passage as a standalone measure, though its prospects would improve if folded into a larger bipartisan package or exchanged for concessions.
The bill has not accumulated any surfaced votes yet.
Extent of federal intervention: liberals more comfortable with the mandate to tie coinsurance to net price; conservatives see this as overr…
On content alone, the bill is a focused, administratively framed attempt to reduce seniors’ cost‑sharing for a set of chronic drugs — a goa…
Relative to its intended legislative type, this bill is a focused statutory amendment that establishes new cost-sharing rules for a defined class of Part D drugs, but it leaves several operational, fiscal, and oversight…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.